Global Plasma Fractionation Market 2018-2028 - Visiongain Report

LONDON, May 10, 2018 /PRNewswire/ --

Immunoglobulins, Albumins, Clotting Factors, Hyperimmune Globulins, Alpha 1 Antitrypsin Inhibitors (A1PI), C1 Esterase Inhibitors, Primary Immune Deficiency (PID), Secondary Immune Deficiency (SID), Idiopathic Thrombocytopenic Purpura (ITP), Cardiac & Surgery, Emergency Medicine, Haemophilia 

In 2017, the global plasma fractionation market was valued at $24bn and is expected to grow at a CAGR of 9.0% in the first half of the forecast period. In 2017, the immunoglobulins submarket held 44.0% of the global plasma fractionation market.

     (Logo: http://mma.prnewswire.com/media/523989/Visiongain_Logo.jpg )

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 172-page report you will receive 91 tables and 98 figures- all unavailable elsewhere.

The 172-page report provides clear detailed insight into the global plasma fractionation market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope 

• Global Plasma Fractionation market forecasts from 2018-2028

• This report also breaks down the revenue forecast for the global plasma fractionation market by type of product:
• Immunoglobulins
• Albumins
• Clotting Factors
• Hyperimmune Globulins
• Alpha 1 Antitrypsin Inhibitors (A1PI)
• C-1
• Others

• This report also breaks down the revenue forecast for the global plasma fractionation market by type of application:
• Primary Immune Deficiency (PID)
• Secondary Immune Deficiency (SID)
• Idiopathic Thrombocytopenic Purpura (ITP)
• Cardiac & Surgery
• Emergency Medicine
• Haemophilia

• This report also breaks down the revenue forecast for the global plasma fractionation market by regional market:
• North America
• Europe
• Latin America
• Asia-Pacific
• Middle East & Africa

• This report also breaks down the revenue forecast for the global plasma fractionation market by national market:
• US
• Canada
• UK
• Germany
• France
• Spain
• Italy
• Rest of Europe
• Japan
• Rest of APAC

• Our study discusses the selected leading companies that are the major players in the plasma fractionation industry:
• Biotest
• CSL
• Grifols
• Kedrion
• LFB
• OctaPharma
• Shire/Baxalta
• Others

• Our study gives qualitative analysis of the plasma fractionation market. It discusses factors that drive and restrain the market

• Other information included in this report:
• Type of plasma processed in Europe from 1996 - 2012 (3-year increment) for non-profit organizations (source plasma vs recovered plasma, in thousand liters)
• Type of plasma processed in Europe from 1996 - 2012 (3-year increment) for commercial companies (source plasma vs recovered plasma, in thousand liters)
• Cost of plasma protein in Canada by product
• Canadian plasma shipments for fractionation by source
• Immunoglobulin-monthly distribution and 12-month rolling average distribution (2016/2017) for: the US, the UK, Germany, Italy, Spain, Austria, Finland, Greece, Norway, Portugal, Sweden, Switzerland
• Albumin 5%-monthly distribution and 12-month rolling average distribution (2016/2017) for the US

Visiongain's study is intended for anyone requiring commercial analyses for the global plasma fractionation market. You find data, trends and predictions.

Buy our report today Global Plasma Fractionation Market 2018-2028: Immunoglobulins, Albumins, Clotting Factors, Hyperimmune Globulins, Alpha 1 Antitrypsin Inhibitors (A1PI), C1 Esterase Inhibitors, Primary Immune Deficiency (PID), Secondary Immune Deficiency (SID), Idiopathic Thrombocytopenic Purpura (ITP), Cardiac & Surgery, Emergency Medicine, Haemophilia.

To request a report overview of this report please contact Sara Peerun at [email protected] or refer to our website : https://www.visiongain.com/Report/2187/Global-Plasma-Fractionation-Market-2018-2028

List of Companies Mentioned in the Report 

3PEA International

Abbott

ABO Pharmaceuticals

Access Plasma LLC

ADMA Biologics

AOSS Medical Supply

B Positive Plasma LLC

Baxalta

Baxter

Bio Products Laboratory Ltd.

Bio-Blood Components Inc.

BioLife Plasma Services LP

BioLife Plasmazentrum Linz

Biomat USA

Biotest

Blood & Plasma Research Inc.

Blood Centers of America (BCA)

Blood Source

Blue Blood Biotech Corporation

Bowling Green Biologicals Inc.

BPL Plasma Inc.

Canadian Plasma Resources

Cara Plasma s.r.o

Cdp Equity

CSL Behring

CSL Plasma

Emergent BioSolutions

Europlasma GmbH

Fondo Strategico Italiano

Fresenius Kabi

GCAM Inc.

Green Cross Biotherapeutics Inc.

Grifols

Grifols PlasmaCare

Gunsan Plasma technology research center

Haema AG

Haemonetics Corporation

Hellenic National Blood Centre

Héma-Québec

Hemasource

Hemobras

ImmunoTek Bio Centers, LLC

Kamada Ltd.

KEDPlasma LLC

Kedrion

L'Etablissement Français du Sang

LFB

LFB Biomédicaments

Lychem International Ltd.

Marketing Research Bureau Inc.

Nihon Pharmaceutical Co., Ltd

OctaPharma

Octapharma Plasma

Plasmapunkt Wien

Plasmaspendedienst Graz

PreviPharma Consulting GmbH

Prometic Plasma Resources

QualTex Laboratories

Roche Diagnostics

Ruhr Plasma GmbH

Scantibodies Biologics

Shire

The Interstate Companies

Therapure Biopharma Inc.

UNC Hemoderivados

UNICAplasma s.r.o

Wirecard North America

Wuhan Zhong Yuan Rui De Biological Products Co. Ltd.(Ruide)

Yung Shin Pharmaceutical Industries Co.

To see a report overview please e mail Sara Peerun on Sara Peerun on [email protected]

SOURCE Visiongain